Nippon Shinyaku Co. Ltd.

04/16/2024 | Press release | Distributed by Public on 04/16/2024 00:06

Nippon Shinyaku Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW